What question did this study set out to answer?

The study aims to evaluate PDK4 as a biomarker and target for immunotherapy in cancer.

February 25, 2026Discover Oncology0 citationsOpen Access

Multi-dimensional analysis reveals the potential of PDK4 as a tumor biomarker and target for immunotherapy

YDYaxing DengAffiliated Hospital of Southwest Medical University XWXin WangSouthwest Medical University YQYue QiuSichuan University

Key Points

The study aims to evaluate PDK4 as a biomarker and target for immunotherapy in cancer.
Conducted multi-dimensional analysis on PDK4
Evaluated its diagnostic and prognostic capabilities
Assessed potential for personalized treatment
PDK4 shows promise as a pan-cancer biomarker
Identified as a potential target for immunotherapy
Support for personalized cancer treatment approaches

Abstract

PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.

KI fragen

Bookmark

View Full Paper